Table 1.
Patients’ characteristics at baseline
| Number (%) of patients
|
||||
|---|---|---|---|---|
| Cohort A n = 15 (%) | Cohort B n = 17 (%) | Cohort C n = 66 (%) | Totala n = 99 (%) | |
| Age, y | ||||
| Median (range) | 60 (50–79) | 64 (28–76) | 62 (24–82) | 61 (24–82) |
| Gender | ||||
| Male | 5 (33.3) | 4 (23.5) | 38 (57.6) | 47 (47.5) |
| Female | 10 (66.7) | 13 (76.5) | 28 (42.4) | 52 (52.5) |
| Race, n (%) | ||||
| White | 8 (53.3) | 14 (82.4) | 54 (81.8) | 76 (76.8) |
| Black | 0 | 2 (11.8) | 6 (9.1) | 8 (8.1) |
| Other | 7 (46.7) | 1 (5.9) | 6 (9.1) | 15 (15.1) |
| ECOG PS,b n (%) | ||||
| 0 | 6 (40) | 4 (23.5) | 16 (24.2) | 26 (26.3) |
| 1 | 9 (60) | 13 (76.5) | 48 (72.7) | 71 (71.7) |
| Histology, n (%) | ||||
| Squamous | 0 | 2 (11.8) | 5 (7.6) | 7 (7.1) |
| Adenocarcinoma | 15 (100) | 15 (88.2) | 58 (87.9) | 89 (89.9) |
| Large cell | 0 | 0 | 2 (3) | 2 (2) |
| Adenosquamous | 0 | 0 | 0 | 0 |
| NOS | 0 | 0 | 1 (1.5) | 1 (1) |
| Stage at study entry, n (%) | ||||
| IIIb | 2 (13.3) | 0 | 0 | 2 (2) |
| IV | 13 (86.7) | 17 (100) | 66 (100) | 97 (98) |
| Time since diagnosis of advanced NSCLC to consent, mo | ||||
| Median (range) | 33 (5.2–80.4) | 10.8 (0.5–27.3) | 16.7 (3.3–98.3) | 16.7 (0.5–98.3) |
| Prior systemic therapies | ||||
| Median (range) | 2 (1–6) | 2 (1–4) | 2 (1–10) | 2 (1–10) |
Abbreviation: NOS, not otherwise specified.
a
One enrolled patient had an unknown mutation status and was not assigned to a cohort.
b
Two patients had missing information.